alexa Hcc Angiogenic Propriety and Tumor Recurrence in Liver Transplant Recipients

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

Global Summit on Pharmacology and Therapeutics

Vienna, Austria

European Summit on Pharmacology and Toxicology

Vienna, Austria
Hcc Angiogenic Propriety and Tumor Recurrence in Liver Transplant Recipients

Content: Objective: Clinic-pathologic characteristic of hepatocellular carcinoma are mostly accounting for the tumor recurrence after liver transplantation. It is assumed that tumor angiogenesis capability contributes to the rates of post-transplant relapse, as well. The aim of study was to evaluate the contribution of the circulating hematopoietic stem cells (HSCs); endothelial progenitor cells (EPCs) and serum vascular endothelial growth factor (VEGF) to the recurrence of HCC after liver transplantation. Methods: The study was carried out on 49 cirrhotic patients with HCC within the Milan criteria. They were transplanted in 2009 and followed-up for 54 months, so far. The rates of circulating HSCs and EPCs were assessed through a phenotypic analysis of 2 ml of fresh blood in a flow cytometer. Serum VEGF concentration was measured by enzyme-linked immunoassay (ELISA). Histopathology examination of the liver explants was performed for tumor characteristic. The data were analyzed with statistical tests. Results: There were 9 deaths related to the procedure. Of 40 remaining patients the tumor recurred in 6 (15%) prior to 36 months and then in 5 (12.5%) prior to 54 months of observation. The pre-transplant rates of circulating HSCs and EPCs were significantly higher in patients with tumor relapse; Chisq=17.25, p<0.001 and Chisq=13.96, p<0.001, respectively. The differences in the serum VEGF concentration were not significant in this group, however. Conclusion: Tumor angiogenesis capability should be considered as the predictive factor of tumor relapse after liver transplantation.

Citation: Otto WJ, Hołówko WH, Krawczyk MS, Król MA, Wilkowojska UM, et al. (2015) Hcc Angiogenic Propriety and Tumor Recurrence in Liver Transplant Recipients. Pharm Anal Acta 6:343. doi: 10.4172/2153-2435.1000343

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger